Oral Olanzapine — Competitive Intelligence Brief

Oral Olanzapine (Oral Olanzapine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry Small molecule

Target snapshot

Oral Olanzapine (Oral Olanzapine) — Eli Lilly and Company. Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral Olanzapine TARGET	Oral Olanzapine	Eli Lilly and Company	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
full-dose olanzapine	full-dose olanzapine	Kaohsiung Kai-Suan Psychiatric Hospital	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
quetiapine (Seroquel) XR	quetiapine (Seroquel) XR	Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
sodium valproate with Clozapine	sodium valproate with Clozapine	Shanghai Mental Health Center	marketed	Antipsychotic + mood stabilizer combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase
quetiapine fumarate vs risperidone	quetiapine fumarate vs risperidone	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
Quetiapine Immediate Release	Quetiapine Immediate Release	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Sublingual film containing Igalmi	Sublingual film containing Igalmi	BioXcel Therapeutics Inc	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

1. Shanghai Mental Health Center · 10 drugs in this class
2. AstraZeneca · 6 drugs in this class
3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
5. Eli Lilly and Company · 4 drugs in this class
6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
7. Medical University of Vienna · 2 drugs in this class
8. Organon and Co · 2 drugs in this class
9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
10. H. Lundbeck A/S · 2 drugs in this class